AbbVie ends early safety study of experimental drug ABBV-1088
NCT ID NCT06579300
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This study was designed to check the safety and how the body processes an experimental drug called ABBV-1088 in healthy adults from Western, Han-Chinese, and Japanese backgrounds. It also looked at how the drug interacts with another medication (itraconazole). The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 270552
Grayslake, Illinois, 60030, United States
-
CenExel ACT- Anaheim Clinical Trials /ID# 276423
Anaheim, California, 92801, United States
Conditions
Explore the condition pages connected to this study.